Litcius/Paper detail

Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma

Shuangming Kang, Wenjuan Duan, Shangqian Zhang, Dawei Chen, Jianfang Feng, Na Qi

2020Theranostics88 citationsDOIOpen Access PDF

Abstract

The dual-targeted drug delivery system was designed for enhancing permeation of the blood-brain barrier (BBB) and providing an anti-glioma effect. As transferrin receptor (TfR) is over-expressed by the brain capillary endothelial (hCMEC/D3) and glioma cells, a mouse monoclonal antibody, RI7217, with high affinity and selectivity for TfR, was used to study the brain targeted drug delivery system. Muscone, an ingredient of traditional Chinese medicine (TCM) musk, was used as the "guide" drug to probe the permeability of the BBB for drug delivery into the cerebrospinal fluid. This study investigated the combined effects of TCM aromatic resuscitation and modern receptor-targeted technology by the use of muscone/RI7217 co-modified docetaxel (DTX) liposomes for enhanced drug delivery to the brain for anti-glioma effect. Methods: Cellular drug uptake from the formulations was determined using fluorescence microscopy and flow cytometry. The drug penetrating ability into tumor spheroids were visualized using confocal laser scanning microscopy (CLSM). In vivo glioma-targeting ability of formulations was evaluated using whole-body fluorescent imaging system. The survival curve study was performed to evaluate the anti-glioma effect of the formulations.

Topics & Concepts

GliomaLiposomeBlood–brain barrierDrug deliveryIn vivoPharmacologyTransferrin receptorFlow cytometryTargeted drug deliveryChemistryDrugMedicineCancer researchTransferrinImmunologyBiologyBiochemistryInternal medicineCentral nervous systemBiotechnologyOrganic chemistryNanoparticle-Based Drug DeliveryBarrier Structure and Function StudiesDrug Transport and Resistance Mechanisms
Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma | Litcius